-Livemint.com   The interim injunction has been granted till Cipla's application for compulsory licensing of the drug is decided   New Delhi: The Delhi high court on Friday restrained homegrown generic drug maker Cipla Ltd from making and selling Indacaterol, a drug claimed to be patented by Swiss pharma company novartis AG. Indacaterol is a respiratory drug used in the treatment of chronic obstructive pulmonary disease and is sold under the brand name Onbrez. Please...

-Down to Earth Government sidelines its committee of experts to set up new panel to review India's intellectual property rights policy The politics of protecting intellectual property rights (IPR) is becoming more curiouswith the commerce ministry setting up a think tank to draft a national IPR policy while sidelining a committee of experts it had set up earlier. Annoyed academics who were asked to help formulate the policy in July this year...

-The Times of India MUMBAI: Some multinational companies (MNCs) have been delaying the launch of life-saving drugs in India years after getting monopoly rights, while cheaper generic versions of exorbitantly-priced medicines are going off the shelves under the product patenting law. Corporates such as Japanese firm Otsuka Pharmaceuticals, US-based Bristol Myers-Squibb (BMS) and Swiss firm novartis are deferring the launch of medicines critical for treatment of serious non-communicable diseases like cancer, HIV,...

-The Hindu The Working Group on Intellectual Property can serve as a platform where real time solutions to meet India's need for low-cost medicines can be addressed After what seemed like a historic trip for Prime Minister Narendra Modi, which held out the promise of reshaping India-U.S. relations positively, the initiation of the Out-of-Cycle Review (OCR) by the United States Trade Representative (USTR) has brought a sobering reality check as to what...

-The Indian Express The era of globalised markets is also an era of globalised sovereignties. Nation states must constantly sync their policies with global constituencies of policies and citizens. At times, domestic disharmony is the price nation states may be required and willing to pay. The case in point here is the proposed review of the intellectual property rights (IPR) policy, particularly those clauses that are related to pharmaceutical patent policy....